Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Juni 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus

- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C., June 12, 2018 (GLOBE NEWSWIRE) --...
07. Juni 2018 07:30 ET | Quelle: Chimerix, Inc.

Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

DURHAM, N.C., June 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and...
05. Juni 2018 17:29 ET | Quelle: Chimerix, Inc.

Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief...
07. Mai 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix Announces First Quarter 2018 Financial Results

- Landmark AdVance Study Demonstrates Strong Correlation Between Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV...
02. Mai 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference

DURHAM, N.C., May 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today...
30. April 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018

DURHAM, N.C., April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today...
02. April 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference

DURHAM, N.C., April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today...
29. März 2018 16:30 ET | Quelle: Chimerix, Inc.

Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors

DURHAM, N.C., March 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of...
19. März 2018 07:00 ET | Quelle: Chimerix, Inc.

The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk

DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from AdVance,...
07. März 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Present at Cowen and Company 38th Annual Health Care Conference

DURHAM, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today...

Vorherige Seite

Nächste Seite